You're about to create your best presentation ever

Gsk Powerpoint Template

Create your presentation by reusing a template from our community or transition your PowerPoint deck into a visually compelling Prezi presentation.

GSK

Transcript: Rebekah Carulla My name is Rebekah, I'm 20 years old and I'm studying Publicity in social comunication at PUC-Rio. I have two experiences abroad: I've studied at Harrow House in Swanage, a seaside town in England for 2 months when I was 14. Harrow House USA And I've worked for the Walt Disney Company for four months in 2010. I worked on the Pirates of the Caribbean attraction at Magic Kingdom Park. It was an amazing experience. In Brazil I've worked on a web page about advertising and midia called Blue Bus, writing news and posting them on social networks. I'm also studying fashion journalism at SENAC and I had the opportunity to write articles for the famous fashion journalist Iesa RodrigueS web page's during Fashion Rio and Fashion Business. Nowadays I'm working at Dasartes Magazine, a magazine about visual arts. I write news for the web page and make the schedule of exhibitions. I also work in partnership with the marketing team, writing press releases for art galleries, museums and other institutions. In my free time I like to play with my dogs, read, watch movies and martial arts and practice muay thay. watch western movies watch martial arts and practice muay thay. play the piano and violin And I have also organized some editions of a theme party for the night club Pista 3, from the matriz group. Recently I have entered a competition for the agency ogilvy with a project briefing to Eno. The Ogilvy's planning director and a representative woman from ENO have chosen my project as the winner. I did market research with consumers and developed a new product for ENO. REBEKAH CARULLA England Swanage play with my dogs

GSK

Transcript: STEPHANIE GALVAN OFFENDER PROFILING 174 Administration of Justice East LosAngeles Community College Joseph James DeAngelo Jr. Born in Bath N.Y., November 8, 1945. Son of Joseph James DeAngelo Sr. and Kathleen Louise Degroat. 2 sisters, Connie and Rebecca & 1 brother,John. At age 10 saw his 7 year old sister get raped. Graduated Folsom HS in Sac, CA in 1964. DeAngelo parents Divorce in 64' Mother remarries in 65 to Jack Bosanko. Background Introduction 1964 1968-1970 1971 Visalia Ransacker East Area Rapist Original Night Stalker Golden State Killer Names Exeter Police Department May 1973-August 1976 Life after Graduation Post-grad work.... Auburn Police Department 1976-1979 DeAngelo marries to Sharon Huddle in November of 1973. 3 Profiles After a Law Enforcement career ends.....a terrorizing criminal career begins.... Gets caught shoplifting The Visalia Ransacker begun of April 1974 and ended in December 1976. -Responsible for 120 Burglaries and one murder. -Target single family homes. -Tear up homes and steal small items. -1st murder occured in Sept of 1975 of Claude Snelling. -Shortly after the V.R. 1st murder occured suspect moved away from Visalia and went to Auburn where crime and terror arose. ***VISALIA RANSACKER SOON TRANSITIONED INTO...**** Claude Snelling The Visalia Ransacker was believed to have moved to Sacramento. -Burglary to Rape. -Crimes usually Occured in Citrus Heights, Rancho Cordova,and Carmicheal. -He survellienced each neighborhood, learned peoples routines, and proweled before attacking. -E.A.R. would frequently call victims before the attack, sometimes months in advance. And after the attack he would call to threaten and scare V. -E.A.R. preferred attacking couples, but often got women alone or with children. -Couples was his preferenece. Gave him a sense of control and power. -After being in Sacramento he striked in 1977 in San Joaquin County then went back to Sac. -After attacking 5 times in 1978 in Modesto the Last Rape occured of July in 1979 with the same M.O. of the E.A.R. that would change moving to Socal.... East Area Rapist First struck in Santa Barbra in October of 1979 where his first victim Anne Lane and her Husband survived The M.O. of the suspect remains breaking in homes, stalking, raping but now adding killing to the profile of the Orginal Night stalker. December of 1979 a couple is shot and Killed, Robert Offerman and Rebra Manning. Of March 1980 Charlene & Lyman Smith were both beaten to death by a woodpile, and wife was raped. August 1980 Keither &Patrice Harrington both bludgeoned to death, wife was raped. February of 1981 Manuela Witthuhn was raped and murdered. July of 1981 Cheri Domingo & Gregory Sanchez were mudered. Sanchez was shot then bludgeoned to death by Gardening tool and Domingo was raped and beaten. May of 1986 Janelle Cruz was raped and bludgeoned to death by pipe wrench. "Original Night Stalker" Offerman and Manning Results Modus Operandi Visalia Ransacker: Routes Entry Warning Signs Vandalize East Area Rapist: Single family homes Stalked middle class . Open Space Learned routines Original Night Stalker: Same MO's as the Visialia Ransacker and E.A.R., except killed victims with a weapon. Analysis Trophies Driver Licenses Jewerly-Wedding Bands Subtopic 1 DeAngelo... was an Organized Killer Disorganized VS. Organized Socially inadequate unskilled work spontaneous offense sloppy Depersonalizes victim Impulsive Lives close to crime no restraints Methodical Maintain control over crime scene Follow crimes on media Skilled work experience Missing weapon or evidence restrains personalies victim crime scene reflects control Brings weapons to scene GSK was ORGANIZED Subtopic 2 Capture After four decades of this case being cold how did the GSK finally get captured???? Investigator and DNA expert Paul Holes used DNA recovered from a crime scene to find the killers great-great grandparents through uploading the DNA found at crime scenes onto 23andme.come and Ancestry.com, where he then was able to create a family tree which led to DeAngelo. DeAngelo at age 72, was locally living in Citrus Heights where he was arrested. Conclusion THANK YOU !!

GSK

Transcript: GlaxoSmithKline GSK company GSK Overview is a global pharmaceutical, biologics, vaccines and consumer healthcare company headquartered in London, United Kingdom. It is world’s third largest pharmaceutical company measured by revenues after Johnson and Johnson and Pfizer. It has a portfolio of products for major disease area including asthma, cancer, virus control, infections, mental health, diabetes and digestive conditions. Statistics what about? British pharmaceutical company, established in 2000. Leading market share in 4 of the 5 largest therapeutic markets– anti infective ,central nervous system, respiratory, and gastrointestinal/metabolic.. 1,100 prescriptions are written for one of its products every minute. Spends over $450,000 every hour on R & D. Number of Employee : 99,300 (2016) Revenue : £ 28.4 billion (2010) History History Today Expanded Established In 2001 it completed its purchase of New Jersey-based Block Drug. On 16 November 2009 the US FDA announced that a vaccine for 2009 H1N1 influenza protection manufactured by GSK's ID Biomedical Corp. subsidiary would join the four approved vaccines. In November 2009 GlaxoSmithKline (85%) formed a joint venture with Pfizer (15%) to create ViiV Healthcare for HIV based drugs. In June 2010, the company acquired Laboratories Phoenix for $253m, which is an Argentine pharmaceutical company focused on the development, marketing and sale of branded generic products. 2000 Merger of Glaxo Wellcome and SmithKline Beecham creates GlaxoSmithKline plc, known as GSK. A year later, we acquire Block Drug Co. adding a wider range of consumer products to our portfolio. 2004 Clinical Trial Register launched. GSK is the first company to launch an online site of clinical trial data accessible to all. 2009 Stiefel acquired and ViiV Healthcare launched. GSK becomes a leader in skincare with the acquisition of Stiefel. GSK and Pfizer launch ViiV Healthcare, a company focused on delivering advances in treatment and care for HIV communities. 2011 Human Genome Sciences and GSK receive approval for Benlysta, the first new lupus treatment in 50 years. 2012 GSK is an official supplier to the London 2012 Olympic and Paralympic Games, providing official laboratory services for anti-doping measures. 2014 Phase III trial concludes for the world’s first malaria vaccine candidate, RTS,S. The pilot implementation will begin in Ghana, Kenya and Malawi. 2015 Major 3-part transaction with Novartis. GSK and Novartis create joint Consumer Healthcare venture. GSK acquires the Novartis global Vaccines business and divests its marketed Oncology portfolio business to Novartis. 2016 Sensodyne becomes GSK’s first consumer brand to reach £1bn in sales. 2017 GSK launches three new products: Shingrix, a vaccine to help prevent shingles in people aged 50 or older; triple therapy inhaler Trelegy Ellipta, for patients with COPD; and Juluca, the first 2-drug regimen for people living with HIV. 2018 To support advances in the development of new medicines, GSK embarks on a major research initiative to sequence genetic data from 500,000 volunteer participants in the UK Biobank healthcare resource. Products Products Product 1 Augmentin® Film-coated tablet for oral use. treatment of infections ( Acute otitis media, Community acquired pneumonia, Cystitis,…ect) (amoxicillin/clavulanate potassium) Product 2 Advair ® (salmeterol, fluticasone propionate) ADVAIR DISKUS is a prescription medicine used to treat asthma in patients 4 years and older. ADVAIR HFA is a prescription medicine used to treat asthma in patients 12 years and older. ADVAIR is not for adults and children with asthma who are well controlled with an asthma control medicine, such as an inhaled corticosteroid (ICS) medicine. ADVAIR is for adults and children with asthma who need both an ICS and long-acting beta2-adrenergic agonist (LABA) medicine. Product 3 Dyazide ® This drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is a combination of two "water pills" (diuretics): triamterene and hydrochlorothiazide. This combination is used by people who have developed or are at risk for having low potassium levels on hydrochlorothiazide. It causes you to make more urine, which helps your body get rid of extra salt and water. (hydrochlorothiazide/triamterene) News In 2011 , we became the first pharmaceutical company to fundamentally change the way we pay our US sales represintative. By 2015 all our sales professionals around the world will be rewarded on technical knowledge and quality of service, rather than on individual sales targets. 20 July 2018First single-dose medicine to prevent the relapse of P. vivax malaria marks a major contribution towards malaria eradication efforts. 18 July 2018ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, will be presenting over 20 abstracts, Stock

GSK

Transcript: Where? 96,500 employees in over 100 countries What's the future of healthcare? Can one person make a difference? YES Why? Is GSK right for you? What's in it for you? A tailored and structured development plan to ensure you build and develop your competencies Where will GSK take me? of GSK's turnover comes from emerging markets - People leadership - Managing complexity - Stakeholder management - Strategic development - Technical capability Integrity Commercial Esprit (Vaccines) - Key Experiences: Community Investment - Stretch and challenging commercial roles to ensure robust learning -Global assignments providing good international breadth -Access to senior leaders across the global business - Coaching, mentoring, support and differentiated development - Flexible/tailored programme to meet individual and business needs Turnover Apply online at: Respect for People of total sales spent in R&D Questions? Esprit Finance Programme Structure Transparency Applications Close "I want GSK to be a very successful company, but not by leaving the population of Africa behind," We look to offer within 2 weeks 14% www.gskbigquestions.com £222m Offer Key Capabilities Built: Vaccines supplied to 179 countries GSK's Values and Culture Telephone or face to face, dependent on the market and programme you apply into Late stage assets in R&D pipeline Join GSK "I'm in charge of an organization that can actually make a difference for people in the third world, and I am not going to be the person who, after X years, sits back and says "Oh, I wish I'd done more."" £28.4bn Who are we looking for? Core Capabilities Assessment Centre Argentina, Brazil, China, Indonesia, Japan, Malaysia, Turkey, Vietnam, UAE and UK/Europe, US Contact: Rachel Tannebaum Esprit Program Manager Rachel.x.tannebaum@yahoo.com 30 5% Commercial Esprit (Consumer Healthcare) - 1.4bn Access to Medicine Index 15th October Esprit Commercial Programme Structure Why GSK? Interview Patient Focused What? Brazil, Malaysia and UK/Europe, US Commercial Esprit (Pharmaceuticals) - - Sales - Marketing - Business Development - External facing role - Mix of Local, Regional and Central roles Brazil, China, Mexico, Singapore and UK/Europe, US Roles available for candidates with residency in the following countries: 24% of the world's pharmaceutical market 1st Belgium Who? Finance Esprit - Pharmaceuticals and Drugs Biopharmaceuticals Consumer/Nutritional Products How? grow deliver simplify as How do we make a difference? £222m of community investment donated in medicines and cash in 2010 Pulse – Global Employee Volunteer programme Orange Day – Regional Employee Volunteer programme To improve the quality of human life a By enabling people to Do more Feel better Live longer What next? “GSK’s flagship Global Talent Development programme creates a pipeline of multi-skilled, diverse leaders, with the right capabilities and behaviours to deliver solutions to GSK’s future strategic challenges.” On the job development through challenging roles Formal training programmes and structured assessment Opportunity to network and develop relationships with senior leaders Mentoring/Buddy, Coaching and support What is Esprit? Esprit Finance Commercial Pharmaceuticals Consumer Healthcare Vaccines (Belgium only) Global Postgraduate Programme Sales & Line Manager Role Home Market 12-18 months Marketing Role International Role 12-18 months Tailored Role Flexible Location 12 months Transition Role to Long Term Career Path Home Location c. 12 months Annual Esprit Development Weeks Ongoing support and development Key highlights - Global opportunities across one of the Commercial programmes - Ability to make a positive difference to patients, consumers and GSK - Personal career plan during formal programme and beyond - Constant networking opportunities across programmes, Commercial and GSK Entry Role 'Home' Contract 1st Role In Home Location Up to 24 months 2nd Role Out of Home Location Up to 24 months Leadership Role Annual Esprit Development Weeks Ongoing support and development Key highlights - Global opportunities across Finance and the wider business - Ability to make a positive difference to patients, consumers and GSK - Personal career plan during formal programme and beyond - Constant networking opportunities across programmes, Finance and GSK Associate Leadership Development Programme facilitates the development of leadership capabilities and experiences through a series of planned individually tailored rotations - Map development against GSK's strategic priorities and business requirements - Mentoring, coaching, buddy and senior management networking - Ongoing assessment and monitoring to ensure Associates are on track in line with programme expectations - Annual Esprit development workshop week and targeted development throughout Current Associate Roles - Finance Director - Change Management and Transformation - Corporate Finance, Treasury - Business Development -Commercial Finance Partner North

GSK

Transcript: Columbus Research Group LLC 5023 Wellington Way GA 31820 Central Georgia Kidney Specialists, PC 890 Second St. Suite 201 Macon, Ga 31201 GSK Study Protocol Principal Investigator: Sagar Panse (MD) Sub-Investigator: Shannon Reynolds (Nurse Practitioner) Clinical Research Coordinator: Maria E Urdaneta (IMG) (Blinded) Licensed Practical Nurse: Jennifer Carr (Unblinded) PROTOCOL GSK-204837 SITE NUMBER: 237078 Protocol Title: A Phase 3 randomized, double-blind, active-controlled, parallel-group, multi-center study in hemodialysis participants with anemia of chronic kidney disease to evaluate the efficacy, safety and pharmacokinetics of three-times weekly dosing of daprodustat compared to recombinant human erythropoietin, following a switch from recombinant human erythropoietin or its analogs. Short Title Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat Three-times weekly dosing in Dialysis (ASCEND-TD) Based on its mechanism of action to stimulate erythropoiesis via inhibition of hypoxia inducible factor (HIF) prolyl hydroxylase enzymes, daprodustat is postulated to be able to raise and maintain hemoglobin (Hgb) without inducing the supraphysiologic erythropoietin (EPO) concentrations associated with recombinant human EPO (rhEPO) therapy, thereby potentially avoiding blood pressure (BP) elevations, major adverse cardiovascular events (MACE) and other adverse effects associated with high recombinant EPO levels. Objective To compare the safety and tolerability of daprodustat administered three-times weekly to epoetin alfa. Incidence and severity of AEs and serious adverse events (SAEs) The Study A sufficient number of participants, which is expected to be approximately 800 participants, will be screened to achieve approximately 402 randomized participants (268 to daprodustat and 134 to epoetin alfa) STUDY -62 week including, 4 week screening period, 52 week treatment period and 4-6 week follow up period. -Study Period: 14 months -Visits: 19 times same as day as dialysis session -Study Drug three times each week during dialysis session 1. Screening Study: Screening period that last 4 weeks blood test and other procedures 2. Randomization 3.Remaining study visits including the follow up visit: 4 study visit (2 weeks apart: 2 weeks, 4 weeks, 6 weeks, 8 weeks) 4 weeks during taking drug and 52 weeks after the randomization visit. 4. Finally study: Follow up 4-6 weeks after last dose. 5. Stop medicine before completing 52 weeks come back 2 weeks of your last dose and continue study visit 12 weeks. Anemia Anemia is a common complication of CKD. The cause of anemia in this population is multi-factorial. Including relative or absolute deficiency of EPO. Reduced iron availability related to chronic inflammation or acute infection, and gastrointestinal blood loss Anemia is further exacerbated by shortened erythrocyte survival that is associated with the uremic milieu and hemodialysis procedure. Oral Iron Therapy due to gastrointestinal intolerance and IV iron may have an increased risk of infection, congestive heart failure, iron overload or anaphylaxis. rhEPO: In order to achieve target Hgb levels, which are lower than normal Hgb levels, treatment with IV rhEPO markedly increases EPO plasma concentrations to higher than normal levels. Treatment with rhEPOs has been associated with increased cancer-related morbidity and mortality and increased risk of major cardiovascular events (e.g., stroke, myocardial infarction and all-cause mortality) Blood transfusions: These are avoided when possible because of potential alloimmunization which can preclude the possibility of receiving a kidney transplant and risk of infection. Adverse Events Adverse Events Epoetin: Heart problems, faster tumor growth, high blood pressure, blood costs and seizures. Adverse events: Daprodustat: Common cold and diarrhea, Excessive erythropoiesis (polycythemia) leading to thrombosis and/or tissue ischemia Serious Adverse Events: Heart attack, heart failure, pneumonia and blood costs in vascular access site for dialysis. Death, MI, stroke, heart failure, thromboembolic events, thrombosis of vascular accessat Hgb levels which are within the normal range (i.e. notpolycythemic conditions) Inclusion/Exclusion Criteria Inclusion/Exclusion Criteria Inclusion Criteria 1. Age: Participant must be 18 to 99 years of age 2.RhEPO or its analogs 3. Hemoglobinconcentration (measured by HemoCue) within the following range: Hgb Range(inclusive) Week -4 • Hgb 8 to 11.5g/dL1 If Hgb is 11.6 to 11.9 g/dL2(7.2 to 7.4 mmol/L), up to two retests are allowed; the retest value must be between 8 to 11.5 g/dL1 (5 to 7.1 mmol/ L). Day 1 • Hgb 8 to 11 g/dL1(5 to 6.8 mmol/L) and receiving at least the minimum rhEPO or analog dose • Hgb >11to 11.5 g/dL1(6.8to 7.1 mmol/L) and receiving greater than the minimum rhEPO or analog dose 3 INCLUSION CRITERIA INCLUSION CRITERIA 4.Dialysis: On hemodialysis (including hemofiltration or hemodiafiltration)>90 days prior to screening

Now you can make any subject more engaging and memorable